{"title":"Can 99mTc-PSMA SPECT/CT Presenting Mirror Image of 68Ga-PSMA PET/CT Be Used for Response Assessment to 177Lu-PSMA in Metastatic Castration-Resistant Prostate Cancer?","authors":"Monika Hooda, Suraj Kumar, Sarika Prashar, Ravimohan Mavuduru, Baljinder Singh","doi":"10.1097/RLU.0000000000005754","DOIUrl":null,"url":null,"abstract":"<p><p>A 69-year-old man, with a known case of metastatic castration-resistant prostate cancer (mCRPC) underwent 68Ga-PSMA PET/CT and 99mTc-PSMA for evaluation of disease burden and response assessment to 177Lu-PSMA therapy. 99mTc-PSMA provided a mirror image of 68Ga-PSMA. This suggests the potential of 99mTc-PSMA SPECT/CT for disease evaluation and response assessment to PSMA-based radioligand therapies in advanced-stage mCRPC patients, especially when 68Ga-PSMA PET/CT is not available.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.6000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005754","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Can 99mTc-PSMA SPECT/CT Presenting Mirror Image of 68Ga-PSMA PET/CT Be Used for Response Assessment to 177Lu-PSMA in Metastatic Castration-Resistant Prostate Cancer?
A 69-year-old man, with a known case of metastatic castration-resistant prostate cancer (mCRPC) underwent 68Ga-PSMA PET/CT and 99mTc-PSMA for evaluation of disease burden and response assessment to 177Lu-PSMA therapy. 99mTc-PSMA provided a mirror image of 68Ga-PSMA. This suggests the potential of 99mTc-PSMA SPECT/CT for disease evaluation and response assessment to PSMA-based radioligand therapies in advanced-stage mCRPC patients, especially when 68Ga-PSMA PET/CT is not available.
期刊介绍:
Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty.
Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.